Teva sues FDA on generic version of J&J's schizophrenia drug
March 4 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.O(TEVA.TA: Quotazione) said its U.S. unit filed a lawsuit against the U.S. Food and Drug Administration seeking 180-day exclusivity for the Israeli company's generic version of Johnson and Johnson's (JNJ.N: Quotazione) schizophrenia drug Risperdal.
The generic drugmaker is disputing that the health regulator provided legal notice that the patent had been delisted prior to Teva's submission of a challenge to the patent.
Teva is seeking a relisiting of the patent, it said in a statement. (Reporting by Varsha Tickoo in Bangalore; Editing by Himani Sarkar)
© Thomson Reuters 2017 Tutti i diritti assegna a Reuters.